|
|
| |
|
| |
News |
Your location: Home -News |
|
| |
 |
| |
|
| |
Raw material medicine in crossroads
Views：14944 origin：Administrator Add time：2014-9-28
.......................................................................................................................................................................................................................................... |
Some people said that, the reform is never persecuted, at present, production enterprises of raw materials into a corner, not changed to the extent not, from another point of view, which to some extent, has accelerated the pace of raw material medicine industry upgrading and transformation.
The traditional bulk raw material market prosperity in more than a decade later, start collapsing last year. The export of traditional bulk raw material medicine early China into the bottlenecks, and the new growth point has not yet fully formed, the export situation is grim.
With the domestic environmental policy tightening, limiting the clinical use of antibiotics, the traditional bulk raw material demand will decline in the domestic trouble and foreign invasion, are a test of raw material medicine production enterprises. For these enterprises, has reached a crucial moment to reflect on, the adjustment of industrial structure and enterprise strategy.
The history of the most stringent 'limit resistance to' issued, for the fierce competition, product homogenization of serious domestic antibiotic production industry, will "fight" more tragic. "Limit resistance to" shock wave extension in the industrial chain, the upstream antibiotic raw materials enterprises by the most powerful earthquake.
It is understood, the result of market competition make the bulk raw material production has been concentrated in a few large pharmaceutical companies. Such as penicillin and derivative products more than 90% production concentrated in the North China pharmaceutical, Harbin Pharmaceutical Group, Lukang Pharmaceutical, Shijiazhuang pharmaceutical enterprises 4 hands; 98% of the vitamin C production is concentrated in the Northeast Pharmaceutical, Shijiazhuang pharmaceutical, North China Pharmaceutical and Jiangshan pharmaceutical enterprises 4; while the Xinhua Pharmaceutical is antipyretic analgesic category of raw material medicine production enterprises in China the biggest.
Prev锟斤拷Raw material medicine serious excess capacity
Next锟斤拷No information! |
|
|
|
